NEW YORK, NY / ACCESSWIRE / April 11, 2017 / Cytori Therapeutics advanced 25.55% to close at $1.72 on Monday. The stock traded between $1.71 and $2.08 on a large volume spike of 17.7 million shares traded.

On Monday, the company announced that it had received approval from the FDA for its requested Investigational Device Exemption for its clinical trial evaluation of its Cytori Cell Therapy in patients with thermal burn injury. The exemption allows Cytori to bypass certain FDA requirements with less stringent regulations. After market close on Monday, the company announced an underwritten public offering of common stock. Proceeds from the sale of the stock are to be used for working capital, general corporate purposes, and funding for their HABEO and ATI-0918 development programs.

The decision to offer common stock is possible for Cytori under their current BARDA agreement (Biomedical Advanced Research and Development Authority) with the FDA, though some investors questioned both the timing of the decision and the decision itself. The stock price retreated in after-hours trading.

Access RDI's Cytori Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CYTX

Geron advanced 19.53% to close at $2.57 on Monday. The stock traded between $2.45 and $2.73 on volume of 15.3 million shares, over 10 times its average daily volume.

The company announced a positive outcome from the second internal data review of its two clinical trials, IMerge and IMbark. The review for IMerge concluded the benefit/risk profile of the therapy given to the patients has sufficient evidence to support continued development. IMBark is being evaluated for safety and efficacy data, and the results conclude the clinical benefit linked to the therapy should allow the trial to continue without any modification.

IMerge is a clinical trial evaluating imetelstat in a two part assessment. The first part is an FDA Phase 2 assessment. The second part evaluates the drug during a Phase 3 study. In both Phases, the goal is to meet primary efficacy endpoint measurements for the rate of red blood cell transfusion independence, lasting for a period of no less than 8 weeks.

Access RDI's Geron Research Report at: https://ub.rdinvesting.com/news/?ticker=GERN

Our Actionable Research on Cytori Therapeutics Inc. (NASDAQ: CYTX) and Geron Corporation (NASDAQ: GERN) can be downloaded free of charge at Research Driven Investing.

RDI Initiates Coverage on:

Cytori Therapeutics Inc. https://ub.rdinvesting.com/news/?ticker=CYTX

Geron Corporation https://ub.rdinvesting.com/news/?ticker=GERN

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com